Document Detail

Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
MedLine Citation:
PMID:  17214059     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Spasmodic dysphonia (SD) is a focal dystonia and adductor SD is the most common form. The standard treatment for adductor SD is EMG-guided, transcutaneous injections of botulinum toxin into the thyroarytenoid muscle. OBJECTIVE: Report the clinical presentation of SD, treatment with botulinum toxin injection, injection technique, results, and adverse effects. MATERIAL AND METHOD: A reviewed of clinical records of patients diagnosed with SD at the Voice Clinic between April 1999 and December 2004 at Srinagarind Hospital, Khon Kaen University, Thailand. Thirty-seven patients were identified but only twenty-five were treated with EMG-guided botulinum toxin injection to the thyroarytenoid muscle. RESULTS: In the presented 37 patients, SD was more common in women (89%) than men (11%). The median duration of symptoms prior to diagnosis was 12 months: all were the adductor type. The average age at onset was 46 years. The presenting symptoms included influence to the voice (84%), hoarseness (70%), strained or strangled voice (65%), decreased loudness (27%), and breathy voice (22%). A vocal tremor coexisted with dystonia in 60% of the presented patients. Treatment with botulinum toxin injection was carried out on 25 patients for 78 injections (mean, 3 per patient). The time for botulinum toxin to take effect averaged 2.3 days (peak effect, 7 days). The patients received substantial relief from their SD symptoms, an average functional improvement of 39.2% (37.6% initially vs. 76.8% finally). Patients' best voice was achieved within one week and persisted for an average of 13.6 weeks. Side effects from the injections included mild breathiness (68%) and mild choking on fluid (56%). After injection, decreased potential for volume was a common complaint, but since all of the patients experienced increased fluency, they were satisfied. Almost all of the patients returned for repeat injections when the benefit diminished. CONCLUSION: Botulinum toxin therapy has become the standard care for the treatment of SD. An acceptable and flexible treatment plan to produce a balance between decreased spasms and loss of function must be developed for each patient.
Supaporn Srirompotong; Patchareeporn Saeseow; Rattana Taweesaengsuksakul; Samerduan Kharmwan; Somchai Srirompotong
Related Documents :
8312829 - Frontalis suspension for essential blepharospasm unresponsive to botulinum toxin therap...
18533549 - Post-surgical role of botulinum toxin-a injection in patients with head and neck cancer...
18458229 - Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based rev...
19363739 - Botulinum toxin type-a (bt-a) for the treatment of multiple eccrine hydrocystomas.
16238799 - Double-blind study of tolerability and antibody production of unmodified and chemically...
607779 - Lymph transport before and after regional lymphadenectomy as demonstrated with 99tcm. p...
972759 - Silent hydronephrosis, a hazard revisited.
16516739 - Stabilization of the proximal ulnar stump in the sauvé-kapandji procedure by using the ...
24589219 - The assessment of the stability in mandibular setback surgery related to spatial factor...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the Medical Association of Thailand = Chotmaihet thangphaet     Volume:  89     ISSN:  0125-2208     ISO Abbreviation:  J Med Assoc Thai     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2007-01-11     Completed Date:  2007-12-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7507216     Medline TA:  J Med Assoc Thai     Country:  Thailand    
Other Details:
Languages:  eng     Pagination:  2077-80     Citation Subset:  IM    
Department of Otolaryngology, Faculty of Medicine, Khon Kaen University 40002, Thailand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Botulinum Toxins / therapeutic use*
Laryngeal Muscles / drug effects
Middle Aged
Spasm / drug therapy*
Treatment Outcome
Voice Disorders / drug therapy*
Reg. No./Substance:
0/Botulinum Toxins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intensity-modulated radiation therapy in head-and-neck cancer, first report in Thailand.
Next Document:  Sixty-one cases of obturator hernia in Chiangrai Regional Hospital: retrospective study.